Impact of adalimumab on rheumatoid arthritis (RA) outcomes: Comparison of an open-label extension study and a registry-based control group

被引：0
|
作者：
Halpern, M. T. [1 ]
Citaldi, M. [2 ]
Kvien, T. [3 ]
机构：
[1] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA
[2] Abbott Labs, Global Hlth Econ & Outcomes Res, Abbott Pk, IL 60064 USA
[3] Diakonjemmet Hosp, Dept Rheumatol, Oslo, Norway
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [41] Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 8
    Pope, Janet
    Keystone, Edward
    Jamal, Shahin
    Wang, Lisy
    Fallon, Lara
    Woolcott, John
    Lazariciu, Irina
    Haraoui, Boulos
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 879 - 879
  • [42] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS
    Fleischmann, R.
    Hrycaj, P.
    van Hoogstraten, H.
    Mangan, E. K.
    Lin, Y.
    Jayawardena, S.
    Burmester, G. R.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 853 - 853
  • [43] Benefits of transdermal fentanyl in patients with rheumatoid arthritis or with osteoarthritis of the knee or hip: An open-label study to assess pain control
    Pavelka, K
    Le Loet, X
    Bjorneboe, O
    Herrero-Beaumont, G
    Richarz, U
    CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) : 1967 - 1977
  • [44] Long-term outcomes of interruption and retreatment vs. continuous therapy with adalimumab for psoriasis: subanalysis of REVEAL and the open-label extension study
    Papp, K.
    Menter, A.
    Poulin, Y.
    Gu, Y.
    Sasso, E. H.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (05) : 634 - 642
  • [45] Efficacy of Vitamin E in Methotrexate-Induced Hepatotoxicity in Rheumatoid Arthritis: An Open-Label Case-Control Study
    Vaidya, Binit
    Bhochhibhoya, Manisha
    Nakarmi, Shweta
    INTERNATIONAL JOURNAL OF RHEUMATOLOGY, 2020, 2020
  • [46] ABP 501 BIOSMILAR TO ADALIMUMAB: FINAL SAFETY, IMMUNOGENICITY, AND EFFICACY RESULTS FROM AN OPEN-LABEL EXTENSION STUDY
    Cohen, S.
    Pablos, J. L.
    Wang, H.
    Mueller, G. A.
    Kivitz, A.
    Matsumoto, A.
    Krishnan, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 834 - 835
  • [47] Patient-Reported Outcomes of Long-Term Upadacitinib Use in Patients with Rheumatoid Arthritis: Interim Analysis Results of a Phase 2, Open-Label Extension Study
    Strand, Vibeke
    Tundia, Namita
    Friedman, Alan
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [48] Tocilizumab Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis: An Open-label Randomized Controlled Trial
    Kume, Kensuke
    Amano, Kanzo
    Yamada, Susumu
    Hatta, Kazuhiko
    Ohta, Hiroyuki
    Kuwaba, Noriko
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (10) : 2169 - 2171
  • [49] Rheumatoid Arthritis Treatment with Filgotinib: Week 132 Safety Data from a Phase 2b Open-Label Extension Study
    Kavanaugh, Arthur
    Genovese, Mark C.
    Winthrop, Kevin
    Creenwald, Maria
    Ponce, Lucia
    Sosa, Favio Enriquez
    Stanislavchuk, Mykola
    Mazur, Minodora
    Spindler, Alberto
    Cseuz, Regina
    Nikulenkova, Natalya
    Glowacka-Kulesz, Maria
    Szombati, Istvan
    Dudek, Anna
    Mozaffarian, Neelufar
    Greer, Joy
    Kunder, Rebecca
    An, Di
    Meulener, Luc
    Besuyen, Robin
    Alten, Rieke
    Westhovens, Rene
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [50] Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in an open-label, long-term extension study
    Taylor, P.
    Genovese, M.
    Keystone, E.
    Schlichting, D.
    Beattie, S.
    Macias, W.
    Lundmark, J.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2014, 43 : 59 - 59
12345